<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is characterised by beta cell failure, which frequently develops in the setting of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0001845'>Inflammation</z:mp> contributes to the pathophysiology of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by impairing insulin action in peripheral tissues and via reduction of beta cell function </plain></SENT>
<SENT sid="2" pm="."><plain><z:mp ids='MP_0001845'>Inflammation</z:mp> may also play an important role in the development of complications that arise in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Hence, the anti-inflammatory actions of commonly used <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering drugs may contribute, indirectly, to their mechanisms of action and therapeutic benefit </plain></SENT>
<SENT sid="4" pm="."><plain>Herein we highlight the anti-inflammatory actions of glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1), which exerts direct and indirect actions on immune function </plain></SENT>
<SENT sid="5" pm="."><plain>The observations that GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> exert anti-inflammatory actions in preclinical studies, taken together with case reports linking improvements in <z:hpo ids='HP_0003765'>psoriasis</z:hpo> with GLP-1 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> therapy, illustrates the emerging clinical implications of non-classical anti-inflammatory actions of incretin-based therapeutics </plain></SENT>
</text></document>